Key clinical point: Combination of low-dose cytarabine (LDAC) with venetoclax vs. placebo improved survival and treatment response in treatment-naive patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC).

Major finding: LDAC+venetoclax vs. LDAC+placebo improved median overall survival (hazard ratio 0.70; P = .04), along with higher rates of complete response (CR) or CR with incomplete hematologic recovery (48.3% vs. 13.2%; P < .001) and postbaseline red blood cell and platelet transfusion independence (39.2% vs. 17.6%; P = .002).

Study details: This was a post hoc analysis performed after an additional 6 months of follow-up of the phase 3 VIALE-C trial, including 211 adult patients with AML who were treatment-naive and unsuitable for IC. Patients were randomly assigned to receive LDAC with venetoclax (n = 143) or placebo (n = 68).

Disclosures: This study was sponsored by AbbVie. Some investigators, including the lead author, reported receiving research and financial support from, being on advisory boards or boards of directors for, being a current or former employee of, holding stocks in, or receiving patents and royalties from various pharmaceutical companies, including AbbVie.

Source: Wei AH et al. Blood Cancer J. 2021;11:163. doi: 10.1038/s41408-021-00555-8.

Key clinical point: Combination of low-dose cytarabine (LDAC) with venetoclax vs. placebo improved survival and treatment response in treatment-naive patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC).

Major finding: LDAC+venetoclax vs. LDAC+placebo improved median overall survival (hazard ratio 0.70; P = .04), along with higher rates of complete response (CR) or CR with incomplete hematologic recovery (48.3% vs. 13.2%; P < .001) and postbaseline red blood cell and platelet transfusion independence (39.2% vs. 17.6%; P = .002).

Study details: This was a post hoc analysis performed after an additional 6 months of follow-up of the phase 3 VIALE-C trial, including 211 adult patients with AML who were treatment-naive and unsuitable for IC. Patients were randomly assigned to receive LDAC with venetoclax (n = 143) or placebo (n = 68).

Disclosures: This study was sponsored by AbbVie. Some investigators, including the lead author, reported receiving research and financial support from, being on advisory boards or boards of directors for, being a current or former employee of, holding stocks in, or receiving patents and royalties from various pharmaceutical companies, including AbbVie.

Source: Wei AH et al. Blood Cancer J. 2021;11:163. doi: 10.1038/s41408-021-00555-8.

Key clinical point: Combination of low-dose cytarabine (LDAC) with venetoclax vs. placebo improved survival and treatment response in treatment-naive patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC).

Major finding: LDAC+venetoclax vs. LDAC+placebo improved median overall survival (hazard ratio 0.70; P = .04), along with higher rates of complete response (CR) or CR with incomplete hematologic recovery (48.3% vs. 13.2%; P < .001) and postbaseline red blood cell and platelet transfusion independence (39.2% vs. 17.6%; P = .002).

Study details: This was a post hoc analysis performed after an additional 6 months of follow-up of the phase 3 VIALE-C trial, including 211 adult patients with AML who were treatment-naive and unsuitable for IC. Patients were randomly assigned to receive LDAC with venetoclax (n = 143) or placebo (n = 68).

Disclosures: This study was sponsored by AbbVie. Some investigators, including the lead author, reported receiving research and financial support from, being on advisory boards or boards of directors for, being a current or former employee of, holding stocks in, or receiving patents and royalties from various pharmaceutical companies, including AbbVie.

Source: Wei AH et al. Blood Cancer J. 2021;11:163. doi: 10.1038/s41408-021-00555-8.

Key clinical point: Salvage chemotherapy with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (Mito-FLAG) was effective and well-tolerated in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). However, consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is essential for long-term disease-free survival.

Major finding: Overall, 56.1% and 19.7% of patients achieved complete remission (CR) or CR with incomplete hematologic recovery and partial remission, respectively. The median overall survival (OS), 30-day mortality, and 60-day mortality were 13 (95% CI 10.2-15.8) months, 4.5%, and 7.6%, respectively. The median OS was superior in patients who underwent allo-HSCT (75.8%) vs. those who did not (17 months vs. 3 months; P < .001).

Study details: This retrospective study included 66 patients with R/R AML receiving Mito-FLAG treatment followed up for a median duration of 54 months.

Disclosures: This study did not receive any funding other than Open Access funding enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Mühleck R et al. J Cancer Res Clin Oncol. 2021 Oct 5. doi: 10.1007/s00432-021-03821-1.

Key clinical point: Salvage chemotherapy with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (Mito-FLAG) was effective and well-tolerated in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). However, consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is essential for long-term disease-free survival.

Major finding: Overall, 56.1% and 19.7% of patients achieved complete remission (CR) or CR with incomplete hematologic recovery and partial remission, respectively. The median overall survival (OS), 30-day mortality, and 60-day mortality were 13 (95% CI 10.2-15.8) months, 4.5%, and 7.6%, respectively. The median OS was superior in patients who underwent allo-HSCT (75.8%) vs. those who did not (17 months vs. 3 months; P < .001).

Study details: This retrospective study included 66 patients with R/R AML receiving Mito-FLAG treatment followed up for a median duration of 54 months.

Disclosures: This study did not receive any funding other than Open Access funding enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Mühleck R et al. J Cancer Res Clin Oncol. 2021 Oct 5. doi: 10.1007/s00432-021-03821-1.

Key clinical point: Salvage chemotherapy with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (Mito-FLAG) was effective and well-tolerated in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). However, consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is essential for long-term disease-free survival.

Major finding: Overall, 56.1% and 19.7% of patients achieved complete remission (CR) or CR with incomplete hematologic recovery and partial remission, respectively. The median overall survival (OS), 30-day mortality, and 60-day mortality were 13 (95% CI 10.2-15.8) months, 4.5%, and 7.6%, respectively. The median OS was superior in patients who underwent allo-HSCT (75.8%) vs. those who did not (17 months vs. 3 months; P < .001).

Study details: This retrospective study included 66 patients with R/R AML receiving Mito-FLAG treatment followed up for a median duration of 54 months.

Disclosures: This study did not receive any funding other than Open Access funding enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Mühleck R et al. J Cancer Res Clin Oncol. 2021 Oct 5. doi: 10.1007/s00432-021-03821-1.

Key clinical point: Intensification of induction II chemotherapy with mitoxantrone and high-dose cytarabine (MA) did not improve survival, but increased toxicity in pediatric patients with high-risk acute myeloid leukemia (AML) vs. cytarabine/daunorubicin/etoposide (ADE).

Major finding: Induction II with MA vs. ADE did not improve 5-year disease-free survival (P = .632) and overall survival (P = .658). Fewer patients receiving MA vs. ADE achieved neutrophil (52.6% vs. 79.3%; P = .011) and platelet (60.0% vs. 82.8%; P = .024) recovery.

Study details: This study included 124 patients with newly diagnosed de novo high-risk AML treated in AAML0531 (n = 29) and AAML1031 (n = 95) trials. For induction II, patients in AAML0531 received ADE and those in AAML1031 received MA. Also, stem cell transplant conditioning used busulfan/cyclophosphamide in AAML0531 and busulfan/fludarabine along with liberalized donor eligibility in AAML1031 trials.

Disclosures: This study was supported by grants from the COG NCTN Network Group Operations Centres and NCTN Statistics and Data Center. M Loken and LE Brodersen reported being an employee of Hematologics Inc.

Source: Elgarten CW et al. Pediatr Blood Cancer. 2021 Oct 1. doi: 10.1002/pbc.29281.

Key clinical point: Intensification of induction II chemotherapy with mitoxantrone and high-dose cytarabine (MA) did not improve survival, but increased toxicity in pediatric patients with high-risk acute myeloid leukemia (AML) vs. cytarabine/daunorubicin/etoposide (ADE).

Major finding: Induction II with MA vs. ADE did not improve 5-year disease-free survival (P = .632) and overall survival (P = .658). Fewer patients receiving MA vs. ADE achieved neutrophil (52.6% vs. 79.3%; P = .011) and platelet (60.0% vs. 82.8%; P = .024) recovery.

Study details: This study included 124 patients with newly diagnosed de novo high-risk AML treated in AAML0531 (n = 29) and AAML1031 (n = 95) trials. For induction II, patients in AAML0531 received ADE and those in AAML1031 received MA. Also, stem cell transplant conditioning used busulfan/cyclophosphamide in AAML0531 and busulfan/fludarabine along with liberalized donor eligibility in AAML1031 trials.

Disclosures: This study was supported by grants from the COG NCTN Network Group Operations Centres and NCTN Statistics and Data Center. M Loken and LE Brodersen reported being an employee of Hematologics Inc.

Source: Elgarten CW et al. Pediatr Blood Cancer. 2021 Oct 1. doi: 10.1002/pbc.29281.

Key clinical point: Intensification of induction II chemotherapy with mitoxantrone and high-dose cytarabine (MA) did not improve survival, but increased toxicity in pediatric patients with high-risk acute myeloid leukemia (AML) vs. cytarabine/daunorubicin/etoposide (ADE).

Major finding: Induction II with MA vs. ADE did not improve 5-year disease-free survival (P = .632) and overall survival (P = .658). Fewer patients receiving MA vs. ADE achieved neutrophil (52.6% vs. 79.3%; P = .011) and platelet (60.0% vs. 82.8%; P = .024) recovery.

Study details: This study included 124 patients with newly diagnosed de novo high-risk AML treated in AAML0531 (n = 29) and AAML1031 (n = 95) trials. For induction II, patients in AAML0531 received ADE and those in AAML1031 received MA. Also, stem cell transplant conditioning used busulfan/cyclophosphamide in AAML0531 and busulfan/fludarabine along with liberalized donor eligibility in AAML1031 trials.

Disclosures: This study was supported by grants from the COG NCTN Network Group Operations Centres and NCTN Statistics and Data Center. M Loken and LE Brodersen reported being an employee of Hematologics Inc.

Source: Elgarten CW et al. Pediatr Blood Cancer. 2021 Oct 1. doi: 10.1002/pbc.29281.

Key clinical point: Addition of quizartinib to low-dose ara-C (LDAC) vs. LDAC alone improved survival and response in older patients with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation who were unfit for intensive chemotherapy (IC).

Major finding: Among patients with FLT3-ITD mutation, LDAC+quizartinib improved response in 38% of patients vs. 0% of patients receiving LDAC alone (P = .02). The 2-year overall survival also improved significantly in patients receiving LDAC+quizartinib (hazard ratio 0.36; P = .024).

Study details: This study included 202 older patients with AML (de novo AML 63%; secondary AML 25%; high-risk myelodysplastic syndrome 11%) unsuitable for IC with (n = 27) or without FLT3-ITD mutation randomly assigned to receive LDAC+quizartinib or LDAC alone.

Disclosures: This study was supported by UK National Institute for Health Research, Blood Cancer UK, and Daiichi Sankyo. Some investigators reported being on advisory boards for, receiving research funding and honoraria from, or being an employee of various pharmaceutical companies, including Daiichi Sankyo.

Source: Dennis M et al. Blood Adv. 2021 Oct 1. doi: 10.1182/bloodadvances.2021005038.

Key clinical point: Addition of quizartinib to low-dose ara-C (LDAC) vs. LDAC alone improved survival and response in older patients with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation who were unfit for intensive chemotherapy (IC).

Major finding: Among patients with FLT3-ITD mutation, LDAC+quizartinib improved response in 38% of patients vs. 0% of patients receiving LDAC alone (P = .02). The 2-year overall survival also improved significantly in patients receiving LDAC+quizartinib (hazard ratio 0.36; P = .024).

Study details: This study included 202 older patients with AML (de novo AML 63%; secondary AML 25%; high-risk myelodysplastic syndrome 11%) unsuitable for IC with (n = 27) or without FLT3-ITD mutation randomly assigned to receive LDAC+quizartinib or LDAC alone.

Disclosures: This study was supported by UK National Institute for Health Research, Blood Cancer UK, and Daiichi Sankyo. Some investigators reported being on advisory boards for, receiving research funding and honoraria from, or being an employee of various pharmaceutical companies, including Daiichi Sankyo.

Source: Dennis M et al. Blood Adv. 2021 Oct 1. doi: 10.1182/bloodadvances.2021005038.

Key clinical point: Addition of quizartinib to low-dose ara-C (LDAC) vs. LDAC alone improved survival and response in older patients with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation who were unfit for intensive chemotherapy (IC).

Major finding: Among patients with FLT3-ITD mutation, LDAC+quizartinib improved response in 38% of patients vs. 0% of patients receiving LDAC alone (P = .02). The 2-year overall survival also improved significantly in patients receiving LDAC+quizartinib (hazard ratio 0.36; P = .024).

Study details: This study included 202 older patients with AML (de novo AML 63%; secondary AML 25%; high-risk myelodysplastic syndrome 11%) unsuitable for IC with (n = 27) or without FLT3-ITD mutation randomly assigned to receive LDAC+quizartinib or LDAC alone.

Disclosures: This study was supported by UK National Institute for Health Research, Blood Cancer UK, and Daiichi Sankyo. Some investigators reported being on advisory boards for, receiving research funding and honoraria from, or being an employee of various pharmaceutical companies, including Daiichi Sankyo.

Source: Dennis M et al. Blood Adv. 2021 Oct 1. doi: 10.1182/bloodadvances.2021005038.

Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.